Last week, Merck informed Ariad that it is terminating its license agreement for the global development and commercialization of ridaforolimus in oncology (Press release Ariad, FEB 25, 2014, View Source [SID:1234500135]). By the terms of the agreement, this becomes effective in November 2014 at which time all rights related to ridaforolimus in oncology will be returned to Ariad.